

PRESS RELEASE

CytoSolve releases in silico models of pancreatic cancer stroma

Cambridge, July 29, 2016: In an effort to advance the complexity of the current in silico models of pancreatic cancer, CytoSolve released the latest version which incorporated the complex interactions of the pancreatic cancer cell with the other cell types in the tumor microenvironment.

"As our understanding of the pancreatic cancer has evolved, it is necessary to analyze the interactions the cancer cell has with its microenvironment. This microenvironment contains several stromal cells including fibroblasts, immune cells, endothelial cells, and myeloid-derived suppressor cells (MDSCs). Our research team has conducted an exhaustive systematic bioinformatics literature review that mined the molecular mechanism involved within each of these cells and between these cells and the cancer cells that are involved in the pathogenesis of pancreatic cancer. We successfully translated the understanding of molecular mechanisms into predictive mathematical models. These models also have been validated using the existing scientific studies to make sure they represent reality," said Dr. Prabhakar Deonikar, Director of Research at CytoSolve.

"We are grateful to Dr. Sunil Krishnan and Dr. Anirban Maitra for their valuable feedback during this update of the pancreatic cancer in silico models. As per the licensing agreement, PancreaSolve has the exclusive right to use the latest version of pancreatic cancer in silico models," said Dr. V. A. Shiva Ayyadurai, Chairman and C.E.O. of CytoSolve, Inc.

CytoSolve is headquartered in Cambridge, MA. CytoSolve's revolutionary technology for in silico mechanistic modeling is accelerating discovery and development of single and multi-combination therapeutics.

PancreaSolve is headquartered in Cambridge, MA. PancreaSolve uses CytoSolve's revolutionary technology for in silico mechanistic modeling to accelerate discovery and development of single and multi-combination therapeutics for pancreatic cancer.

The University of Texas MD Anderson Cancer Center is one of the world's most respected centers devoted exclusively to cancer patient care, research, education and prevention. It is a premier cancer center in the world, based on the excellence in research-driven patient care and cutting-edge science.